Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis (Ixora-peds)

I1F-MC-RHCD -

The purpose of this study is to evaluate the safety and efficacy of ixekizumab in pediatric participants with moderate-to-severe plaque psoriasis. Note: the study design may differ if you reside outside of US or Canada, please consult with the appropriate investigator for more details.

Trial Summary

Age Range
6 - 17 years
Conditions the trial is for
Plaque Psoriasis
What the trial is testing?
Etanercept, Ixekizumab
Could I receive a Placebo?
Yes
Enrollment Goal
201
Trial Dates
Mar 28, 2017 - Mar 23, 2021
How long will I be in the trial?
Your participation could last up to 132 weeks and include 34 visits to the study center.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participant (child or adolescent) must have a diagnosis of moderate-to-severe plaque-type psoriasis for at least 6 months prior to baseline as determined by the investigator

  • Male participant must agree to use a reliable method of birth control during the study

  • Female participant of childbearing potential must test negative for pregnancy and agree to use a reliable method of birth control or agree not to be sexually active during the study and for at least 12 weeks following the last dose of study medication

  • Participant and their parent or legal guardian must be able to understand and fully participate in the activities of the clinical study

Participants Must Not:

  • Participant must not have any active or recent infection within 4 weeks of the first dose of study medication

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.